134 related articles for article (PubMed ID: 30663155)
21. [Oral chemotherapy for advanced breast cancer].
Nakagawa M; Morimoto M; Tangoku A
Nihon Rinsho; 2012 Sep; 70 Suppl 7():587-91. PubMed ID: 23350468
[No Abstract] [Full Text] [Related]
22. Microcystic adnexal carcinoma: successful management of a large scalp lesion.
Kim LH; Teston L; Sasani S; Henderson C
J Plast Surg Hand Surg; 2014 Apr; 48(2):158-60. PubMed ID: 23968368
[TBL] [Abstract][Full Text] [Related]
23. [Microcystic adnexal carcinoma. A case report].
Cortelazzi R; Politi M; Consolo U; Bonetti F; Colombari R
Minerva Stomatol; 1990 Jul; 39(7):529-33. PubMed ID: 2280750
[TBL] [Abstract][Full Text] [Related]
24. [Pharmacokinetics of 5-FU after S-1 oral administration for adjuvant chemotherapy in gastric cancer patients].
Matsumoto H; Hirai T; Hirabayashi Y; Murakami H; Higashida M; Kawabe Y; Fuchimoto M; Fujikura H; Hato S; Urakami A; Yamashita K; Tsunoda T
Gan To Kagaku Ryoho; 2007 Jun; 34(6):869-73. PubMed ID: 17565248
[TBL] [Abstract][Full Text] [Related]
25. [Evaluation of the efficacy of TS-1 for peritoneal dissemination of gastric cancer using a newly-developed animal model].
Mori T; Fujiwara Y; Takiguchi S; Yasuda T; Tamura S; Yano M; Monden M
Nihon Geka Gakkai Zasshi; 2002 May; 103(5):448. PubMed ID: 12048883
[No Abstract] [Full Text] [Related]
26. [A case of oral squamous cell carcinoma responding to S-1].
Harada K; Tamatani T; Bando T; Yoshida H
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1455-8. PubMed ID: 17876145
[TBL] [Abstract][Full Text] [Related]
27. [S-1 for treatment of breast cancers].
Saeki T; Takashima S
Nihon Rinsho; 2000 Apr; 58 Suppl():284-91. PubMed ID: 11026008
[No Abstract] [Full Text] [Related]
28. [Adjuvant chemotherapy with TS-1 for head and neck cancer--side effect of two-week application followed by one-week rest regimen].
Itoi A; Takashima M; Ishimasa H; Murata H; Tomoda K
Gan To Kagaku Ryoho; 2006 May; 33(5):617-20. PubMed ID: 16685159
[TBL] [Abstract][Full Text] [Related]
29. Microcystic adnexal carcinoma: an unusual cause of swelling and paraesthesia of the lower lip.
Hodgson TA; Haricharan AK; Barrett AW; Porter SR
Oral Oncol; 2003 Feb; 39(2):195-8. PubMed ID: 12509975
[TBL] [Abstract][Full Text] [Related]
30. [A case of local relapsed rectal cancer responding to low-dose S-1].
Nakagawa K; Ueno M; Kanamura T; Kojima Y; Fujita S; Ikeda N
Gan To Kagaku Ryoho; 2010 Nov; 37(12):2638-40. PubMed ID: 21224664
[TBL] [Abstract][Full Text] [Related]
31. Microcystic adnexal carcinoma of the breast: a very rare breast skin tumor.
Yavuzer R; Boyaci M; Sari A; Ataoğlu O
Dermatol Surg; 2002 Nov; 28(11):1092-4. PubMed ID: 12460312
[TBL] [Abstract][Full Text] [Related]
32. Adherence and feasibility of 2 treatment schedules of S-1 as adjuvant chemotherapy for patients with completely resected advanced lung cancer: a multicenter randomized controlled trial.
Hata Y; Kiribayashi T; Kishi K; Nagashima M; Nakayama T; Ikeda S; Kadokura M; Ozeki Y; Otsuka H; Murakami Y; Takagi K; Iyoda A
BMC Cancer; 2017 Aug; 17(1):581. PubMed ID: 28851314
[TBL] [Abstract][Full Text] [Related]
33. Effect of intensity modulated radiotherapy combined with s-1-based chemotherapy in locally advanced gastric cancer patients.
Hu JB; Sun XN; Gu BX; Wang Q; Hu WX
Oncol Res Treat; 2014; 37(1-2):11-6. PubMed ID: 24613903
[TBL] [Abstract][Full Text] [Related]
34. Case report: hand-foot syndrome induced by the oral fluoropyrimidine S-1.
Elasmar SA; Saad ED; Hoff PM
Jpn J Clin Oncol; 2001 Apr; 31(4):172-4. PubMed ID: 11386466
[TBL] [Abstract][Full Text] [Related]
35. S-1 is an active anticancer agent for advanced thymic carcinoma.
Okuma Y; Shimokawa T; Takagi Y; Hosomi Y; Iguchi M; Okamura T; Shibuya M
Lung Cancer; 2010 Dec; 70(3):357-63. PubMed ID: 20951466
[TBL] [Abstract][Full Text] [Related]
36. Sclerosing sweat duct carcinoma in an 11-year-old boy.
McAlvany JP; Stonecipher MR; Leshin B; Prichard E; White W
J Dermatol Surg Oncol; 1994 Nov; 20(11):767-8. PubMed ID: 7962941
[TBL] [Abstract][Full Text] [Related]
37. [Concentration of FT and CDHP and 5-FU in the ascites fluid of patient with peritoneal carcinomatosis after new anti-cancer drug TS-1 oral administration].
Iizuka R; Takahashi S; Kakihara N; Matsumura H; Takenaka A
Gan To Kagaku Ryoho; 2002 Jul; 29(7):1251-3. PubMed ID: 12146009
[No Abstract] [Full Text] [Related]
38. Eccrine squamous syringometaplasia of underlying syringoma associated with Tegafur/Gimeracil/Oteracil (TS-1).
Kim J; Kim SH; Lee MG; Chung KY; Kim DS
Acta Derm Venereol; 2015 Nov; 95(8):999-1000. PubMed ID: 25766447
[No Abstract] [Full Text] [Related]
39. Oral administration of the amino acids cystine and theanine attenuates the adverse events of S-1 adjuvant chemotherapy in gastrointestinal cancer patients.
Tsuchiya T; Honda H; Oikawa M; Kakita T; Oyama A; Oishi H; Tochikubo K; Hashimoto T; Kurihara S; Shibakusa T; Kayahara T
Int J Clin Oncol; 2016 Dec; 21(6):1085-1090. PubMed ID: 27306219
[TBL] [Abstract][Full Text] [Related]
40. [Adjuvant chemotherapy using S-1 for curatively resected gastric cancer-the nationwide clinical trial].
Sasako M; Saka M; Fukagawa T; Katai H; Sano T
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():110-6. PubMed ID: 16897984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
